Warnings of Brexit impact on medicines supply
Price hikes on NHS medicines and an increase in red tape on imports could have a serious effect on the post-Brexit UK medicines supply chain and put patient safety at risk, the Healthcare Distribution Association has said. The Association has called for both a transitional period during which the status quo is maintained and the formulation of a sustainable long-term approach.
The Association, which represents businesses that supply medicines, medical devices and healthcare services, was responding to the Health Select Committeeâ€™s Brexit inquiry.
Customs and tariffs
Answering the Committeeâ€™s question regarding the key considerations for companies, healthcare service and regulatory bodies, it outlined scenarios that could see changes to customs and tariffs affect the â€œtimely
and cost-effective supply of medicines to patientsâ€, including prohibitive tariffs on imported medicines and significant increase in the administrative burden for imports before they reach the UK.
In addition, the loss of equivalence with EU legislation would make it difficult for manufacturers to bring products to the UK as quickly as happens currently, the HDA said, adding that â€œgreater clarity on future regulatory and trading relations is required as soon as possible if patient safety is not to be put at risk.â€
The HDA said: â€œThe government must urgently agree not only a transitional arrangement with the EU for these issues, but a long-term and sustainable way forward that provides the medicines supply chain with the much-needed certainty that it requires to deliver the right medicine, in the right place at the right time for patients across the UK.â€
Leaving the common trademarks system and the free movement (or â€˜parallel tradeâ€™) of medicines this allowsâ€“ a state of affairs that could be permanent in the event of a â€˜hard Brexitâ€™ â€“ is also likely to increase the risk of medicines shortages, the HDA said, and could lead to price hikes for NHS medicines.
To avoid these harmful effects, the government â€œmust consider sector-by-sector deals on IP rights, agreeing to mutually recognise certain products, such as pharmaceuticals,â€ the HDA said.Â
Stresses on the supply chain post-Brexit could affect the UKâ€™s ability to implement the Falsified Medicines Directive by the February 2019 target date, the HDA added.